Matthew Herder

@cmrherder

Director, Health Law Institute & Associate Prof, , Dalhousie University, College of New Scholars, he/him

Halifax, Nova Scotia
Vrijeme pridruživanja: rujan 2012.

Tweetovi

Blokirali ste korisnika/cu @cmrherder

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cmrherder

  1. Prikvačeni tweet
    13. kol 2019.

    Published today in the Milbank Quarterly : My qualitative inquiry into the sate of lifecycle regulation

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    "Remember: the Canada Pension Plan and medicare itself were both introduced in the 1960s by a minority government," say Roy Romanow and Greg Marchildon in their argument for now.

    Poništi
  3. proslijedio/la je Tweet
    4. velj

    Quick retraction of faulty coronavirus paper posted to shows value of swift scientific communication to correct/improve faulty science - the process worked - and shows opportunity that can come from earlier learning about each other's work

    Poništi
  4. proslijedio/la je Tweet

    Grant deadline extended. Up to USD $150,000 available for reanalyzing clinical trials - for researchers interested in using unpublished data to publish clinical trials that are either unpublished or were incompletely reported.

    Poništi
  5. 31. sij

    Also lovely to see , a ‘fellow’ Harkness fellow, appear in the list too!

    Prikaži ovu nit
    Poništi
  6. 31. sij

    Wow, really honoured to see that my paper on lifecycle regulation is being read. Huge thanks to for funding the research, colleagues like for critical feedback, and to for a great publishing experience

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    28. sij

    Top universities thrash out a joint position on data sharing as spread shows need for accelerating research

    Poništi
  8. proslijedio/la je Tweet
    28. sij

    Interested in government funding and pricing of resulting products? New piece out by discussing CRADAs and NIH’s reasonable pricing clause

    Tweet je nedostupan.
    Poništi
  9. proslijedio/la je Tweet
    28. sij

    Strong leadership from , launching a divestment campaign "Health professionals and medical organisations should not accept the world as it is ... Taking action is a duty to the people we serve and to future generations."

    Poništi
  10. proslijedio/la je Tweet
    26. sij

    When people talk about missions, I always warn them: if this is something that makes you feel comfortable and happy and cosy, then you haven't understood it, because it's actually about fundamentally changing how we think about innovation.

    Poništi
  11. 24. sij

    Mandatory disclosure + meaningful support for PAOs w/out corporate $ to participate in policy/decision-making processes. Disclosure alone is not enough.

    Poništi
  12. proslijedio/la je Tweet
    24. sij

    A 15% response rate in 62 patients (no control arm) leads to drug approval This is dangerous stuff. If the FDA decides not to enforce an efficacy requirement for new drugs, then patients pay the price with massive uncertainty.

    Poništi
  13. proslijedio/la je Tweet
    22. sij

    Our latest in : Drug company marketing of stimulants is widespread, affected as many as 1 in 18 docs (and 1 in 5 pediatricians) nationwide between 2014-2018. All this amid rising prescribing and potential misuse.

    Poništi
  14. proslijedio/la je Tweet
    22. sij

    The more I read about the approval of Sarepta's golodirsen (Vyondys 53), the more it boggles the mind. FDA's CRL with big concerns about efficacy, safety, and the lack of precedent eteplirsen confirmatory trial (over which the drug was approved anyway):

    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet
    22. sij

    FDA's Unger overruled again on , this time by OND's Stein (last time it was Woodcock)

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet
    22. sij

    --- VICTORY FOR MEDICAL TRANSPARENCY --- European court upholds access to Clinical Study Reports -> excellent news for patients worldwide <-

    , , i još njih 7
    Poništi
  17. proslijedio/la je Tweet
    22. sij

    Based on the last line it certainly looks like the lack of progress in starting a confirmatory trial for etep was a significant concern for the golo NDA as previously reported

    Poništi
  18. proslijedio/la je Tweet

    Merck and PTC Therapeutics lose in their lawsuit against the European Medicines Agency transparency policy: "The Court confirms the right of access to documents contained in the file of a marketing authorisation application for a medicinal product"

    Poništi
  19. 21. sij

    ICYMI - "The Merck [sic] Ebola Vaccine"* published last week co-authored with + *That's the title I always wanted to give it And if you're interested in a deeper dive, here's the talk from March 2019:

    Poništi
  20. proslijedio/la je Tweet
    21. sij

    Great thread, and a great paper led by describing the status of "failure to warn" suits after 2019 decision in Merck v. Albrecht - all you folks on should give it a read

    Poništi
  21. proslijedio/la je Tweet
    20. sij

    In "Pharmaceutical Ethics and Grassroots Activism in the United States: A Social History Perspective", just out in the Journal of Bioethical Inquiry, we look at public health activism in the Progressive Era, the postwar era and the present day.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·